盐酸吉西他滨治疗23例老年晚期非小细胞肺癌的疗效观察

To observe the efficiency of gemcitabine for the treatment of advanced non-small-cell lung cancer in 23 elderly patients.

目的观察吉西他滨单药治疗老年晚期肺癌的疗效、临床受益反应(CBR)及毒副反应。方法23例ⅢB～Ⅳ期老年非小细胞肺癌患者采用吉西他滨1000mg/m2,第1,8天静滴,每21天为1周期。按WHO标准评估疗效及毒副反应,同时评估CBR指标。结果PR6例,NC12例,PD5例,有效率26.1%,CBR为91.3%。毒副反应轻,老年患者也能耐受。结论采用吉西他滨单药治疗疗效好、低毒、安全,可作为老年晚期肺癌患者的一线治疗方案。

Objective To evaluate the clinical efficacy,clinical-binefit-respose （CBR） and toxicity ofgemcitabine single-agent in the treatment of elderly advanced non-small-cell lung cancer patients.Methers 23 elderly patients with great Ⅲ/Ⅳ were treated with gemcitabine 1 000 mg/m^2 on the first and eighth day in each 21-day cycle.The clinical efficacy and toxicity were estimated according to the standard of WHO and the CBR was evaluated simultaneously.Results There were 6 partial resposes, 12 no changes and 5 progressive diseases.The efficiency rate is 26.1%.The CBR rate was reached 91.3% in 23 patients.The toxicity was mild and well tolerated for elderly patients.Conclusions Gemcitabine single-agent in the treatment of elderly advanced non-small-cell lung cancer is highly effective,low toxic and safe.Therefore, it could be considered as the first line therapy for elderly advanced non-small-cell lung cancer patients.